Table 1.
Demographics and general clinical features.
| Treated | Untreated | |
|---|---|---|
| Number of subjects | 21 (100) | 42 (100) |
| Women: n (%) | 19 (90) | 38 (90) |
| Age (years): median (IQR) | 48 (34–56) | 44 (34–55) |
| Disease duration (years): median (IQR) | 12 (7–21) | 11 (6–21) |
| Disease characteristics (history): n (%) | ||
| Musculoskeletal inv. | 19 (90) | 36 (86) |
| Mucocutaneous inv. | 14 (67) | 29 (69) |
| Nephritis | 8 (38) | 9 (21) |
| Neuropsychiatric SLE | 5 (24) | 6 (14) |
| Cardiopulmonary inv. | 5 (24) | 10 (24) |
| Haematological inv. | 15 (71) | 27 (64) |
| Constitutional symptoms | 8 (38) | 11 (26) |
| Gastrointestinal inv. | 3 (14) | 2 (5) |
| Ophthalmic inv. | 3 (14) | 5 (12) |
| Antiphospholipid syndrome | 3 (14) | 3 (7) |
| Serological features (history): n (%) | ||
| Antiphospholipid antibodies | 7 (33) | 18 (43) |
| ADNA | 16 (76) | 32 (76) |
| aSm | 1 (5) | 7 (17) |
| Low complement | 16 (76) | 34 (81) |
| Treatment history | ||
| HCQ ever: n (%) | 18 (86) | 40 (95) |
| MTX ever: n (%) | 7 (33) | 10 (24) |
| MMF ever: n (%) | 11 (52) | 14 (33) |
| AZA ever: n (%) | 14 (67) | 20 (48) |
| CyA ever: n (%) | 4 (19) | 2 (5) |
| CYC ever: n (%) | 4 (19) | 4 (10) |
| RTX ever: n (%) | 5 (24) | 4 (10) |
| Time from last RTX dose (months): median (IQR) | 10 (6–24) | 32 (11–57) |
| High dose glucocorticoids ever: n (%) | 17 (81) | 22 (52) |
Abbreviations: ADNA: anti-DNA antibodies; aSm: anti-Smith antibodies; AZA: azathioprine; CyA: cyclosporine A; CYC: cyclophosphamide; HCQ: hydroxychloroquine; MMF: mycophenolate mofetil; MTX: methotrexate, RTX: rituximab.